Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,200 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06686524RecruitingPhase 1
CD19-targeted UCAR-T for refractory juvenile dermatomyositis
This trial tests a new type of immune cell therapy (UCAR-T) that targets a protein called CD19 to treat children with a severe form of juvenile dermatomyositis that hasn't responded to standard treatments. It aims to calm the overactive immune system and reduce symptoms like muscle weakness and skin rashes.
Hangzhou, ZhejiangAges 5 years+ - NCT07652632Recruiting
Regenerative endoscopy for hard-to-treat Crohn's fistulas
This trial tests a new, less invasive procedure called regenerative endoscopy to repair complex fistulas in people with Crohn's disease. It's for those who haven't gotten better with standard treatments like biologics or surgery.
Hyderabad, TelanganaAges 18–65 - NCT07644286RecruitingPhase 2
Pirfenidone and immunotherapy with optional radiation for advanced colorectal cancer
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
Wuhan, HubeiAges 18–75 - NCT07639138RecruitingPhase 2
Lenalidomide with targeted therapy and immunotherapy for advanced liver cancer
This trial tests whether adding lenalidomide (a drug that boosts the immune system) to your current targeted therapy and immunotherapy can help advanced liver cancer that has progressed after previous treatments. You would be eligible if your cancer has already been treated with at least two prior drug combinations and initially responded before growing back.
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, ChinaAges 18–75 - NCT07639177RecruitingPhase 2
Fecal Microbiota Transplant for Hard-to-Treat Rheumatoid Arthritis
This trial tests whether transferring healthy gut bacteria from a donor to patients with rheumatoid arthritis that hasn't improved on standard medications can reduce joint pain and swelling. The goal is to see if rebalancing the gut microbiome (the community of bacteria in your intestines) helps control inflammation.
Beijing, Beijing MunicipalityAges 18–65 - NCT06691152RecruitingPhase 1
CD19 UCAR T cells for severe lupus
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT05398003Recruiting
Stimulating nerves to treat long-lasting neck and arm pain
This trial tests whether a nerve-stimulation treatment can reduce chronic neck and upper arm pain when other treatments haven’t worked. It includes adults who can consent and attend follow-up visits, and it checks for safety with pregnancy prevention and a specific early test after implantation.
NantesAges 18–85 - NCT03944876RecruitingPhase 3
Botulinum toxin to block a facial nerve for chronic cluster headaches
This trial tests whether injections of botulinum toxin type A can reduce frequent, severe cluster headache attacks by targeting a facial nerve area. It’s for people whose cluster headaches have not responded well—or have caused side effects—to standard preventive treatments.
HamburgAges 18–85 - NCT07630974RecruitingPhase 1/Phase 2
New Cancer Drug for Children With Hard-to-Treat Solid Tumors
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
Los Angeles, CaliforniaAges 1 month–17 years - NCT07635056RecruitingPhase 2
Natural killer cells for hard-to-treat neuroblastoma
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
Cincinnati, OhioAges 1–39 - NCT07637578RecruitingPhase 2
Elranatamab infusions for relapsed or refractory myeloma
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
Denver, ColoradoAges 18 years+ - NCT06693973RecruitingEarly Phase 1
AcNK-Sup003 cell therapy for relapsed B-cell lymphoma
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
Wuhan, HubeiAges 18 years+ - NCT04834024RecruitingPhase 3
MIL62 plus lenalidomide vs lenalidomide alone for rituximab-refractory lymphoma
This trial tests whether adding MIL62 to lenalidomide works better than lenalidomide alone in people with follicular lymphoma that no longer responds to rituximab. The goal is to improve tumor control by using an additional medicine along with standard treatment.
BeijingAges 18 years+ - NCT05254730Recruiting
Testing brain-recording sensors to map the seizure source
This study looks at using special tiny filaments during brain monitoring to better identify where seizures start. It’s meant for people with hard-to-control (refractory) epilepsy who are already being considered for a specific brain-monitoring procedure.
Montreal, QuebecAges Any age - NCT06510283RecruitingPhase 2
Taitacept for refractory or recurrent autoimmune encephalitis
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07623616RecruitingPhase 2
Ziftomenib for relapsed AML with NPM1 mutation
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
ChibaAges 18 years+ - NCT07625293RecruitingPhase 2
DB-3Q for treatment-resistant Crohn's disease
This trial tests a new medicine called DB-3Q for people with Crohn's disease that hasn't responded to standard biologic treatments or causes side effects. The study aims to see if DB-3Q can reduce inflammation and symptoms in people whose disease is hard to control.
St Louis, MissouriAges 18–75 - NCT07629245RecruitingPhase 1/Phase 2
Cell therapy for Crohn's disease fistulas after prior treatment
This trial tests whether injecting your own fat-derived cells combined with a skin graft can heal anal fistulas (abnormal passages near the anus) that didn't respond to or came back after a previous cell therapy study. You must have already participated in the ADICROHN-2 study.
MarseilleAges 18 years+ - NCT05302037RecruitingPhase 1
CAR T cell therapy for advanced cancers that can be targeted
This early-phase study tests a lab-made immune cell treatment that is designed to find and attack tumors that show a specific target on cancer cells. It is for adults with advanced cancers that have not responded well to at least two standard treatments.
SingaporeAges 21 years+ - NCT07617753RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Recurrent Ovarian Cancer
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07620041RecruitingPhase 1
Testing QLC5508, a new cancer drug, in advanced solid tumors
This early-stage trial tests QLC5508, an experimental cancer medication, in patients with advanced solid tumors that haven't responded to standard treatments. The study focuses on safety, how the drug moves through your body, and potential interactions with other medications.
Changchun, JilinAges 18 years+ - NCT06705296RecruitingPhase 1
Deep brain stimulation for severe PTSD
This trial tests whether deep brain stimulation, a surgery that uses a small device to send electrical pulses to specific brain areas, can help people with severe PTSD that hasn't improved after trying several treatments. It aims to see if this approach is safe and effective for long-lasting symptoms.
Toronto, OntarioAges 18–70 - NCT05674552RecruitingPhase 2/Phase 3
Ketone drinks to treat hard-to-stop seizure emergencies
This trial tests whether taking ketone esters (a special form of ketones) can help stop refractory generalized convulsive status epilepticus (a seizure emergency that is hard to control). If you qualify, the study team will check safety closely, especially your breathing, heart stability, and blood sugar/acid levels.
SohagAges 1–10 - NCT07604064RecruitingPhase 2
IDH1 Inhibitor Treatment for Relapsed or Refractory Blood Cancer
This trial tests a drug called olutasidenib in Japanese patients with acute myeloid leukemia (a serious blood cancer) that has come back or stopped responding to previous treatment. The drug targets a specific genetic change (IDH1 mutation) that some leukemia cells have, and may help patients whose cancer is difficult to treat.
Tokyo and Other Japanese CitiesAges 18 years+
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,200 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.